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ERK1 and ERK2 are the effector kinases
of the evolutionarily conserved ERK1/2
MAP-kinase signaling pathway. Using
genetic approaches, Fre´min et al.
demonstrate that ERK1 and ERK2
isoforms exert redundant functions
during mouse development. Transgenic
expression of ERK1 fully rescues the
developmental defects associated with
the loss of ERK2.
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ERK1 and ERK2 are the effector kinases of the
ERK1/2 MAP-kinase signaling pathway, which plays
a central role in transducing signals controlling cell
proliferation, differentiation, and survival. Deregu-
lated activity of the ERK1/2 pathway is linked to a
group of developmental syndromes and contributes
to the pathogenesis of various human diseases.
One fundamental question that remains unad-
dressed is whether ERK1 and ERK2 have evolved
unique physiological functions or whether they are
used redundantly to reach a threshold of global
ERK activity. Here, we show that the extent of devel-
opment of the mouse placenta and embryo bearing
different combinations of Erk1 and Erk2 alleles is
strictly correlated with total ERK1/2 activity. We
further demonstrate that transgenic expression of
ERK1 fully rescues the embryonic and placental
developmental defects associated with the loss of
ERK2. We conclude that ERK1 and ERK2 exert
redundant functions in mouse development.INTRODUCTION
The ERK1/2 MAP kinase pathway is an evolutionarily conserved
signaling module that processes information from a wide spec-
trum of extracellular stimuli to regulate cellular responses such
as proliferation, survival, differentiation, and migration (Chang
and Karin, 2001; Pearson et al., 2001). Perturbation of ERK1/2
signaling as a result of germline gain-of-function or loss-of-func-
tion mutations in pathway components is causally linked to a
group of human congenital disorders characterized by facial
dysmorphism, cardiac malformations, cutaneous and musculo-
skeletal abnormalities, and cognitive impairment (Rauen, 2013;
Samuels et al., 2009). The ERK1/2 pathway is also commonly
deregulated in human cancers and in various other diseases
(Fre´min and Meloche, 2010; Lawrence et al., 2008).
In mammals, signaling by the ERK1/2 pathway is relayed by
the effector kinase isoforms ERK1 and ERK2, which shareC83% amino acid identity (Boulton et al., 1990, 1991). Despite
an abundant literature on this pathway, it is not known whether
ERK1 and ERK2 have evolved specific physiological functions
or whether they are used redundantly. Erk1/ mice are viable
and display no overt phenotype (Page`s et al., 1999), whereas
Erk2/ mice die in utero around embryonic day (E) 6.5, despite
expression of ERK1 in early embryos (Hatano et al., 2003; Saba-
El-Leil et al., 2003; Yao et al., 2003). Various mouse studies have
reported that disruption of Erk1 or Erk2 results in distinct pheno-
typic consequences, arguing for isoform-specific functions of
the two kinases (Bost et al., 2005; Bourcier et al., 2006; Guihard
et al., 2010; Samuels et al., 2009; Satoh et al., 2007). On the other
hand, additional inactivation of Erk1 was found to aggravate the
neural crest and neurogenesis defects of ERK2-deficient mice,
suggesting a gene dosage-dependent contribution of ERK1/2
signaling (Newbern et al., 2008; Satoh et al., 2011). In vitro
studies of the individual roles of ERK1 and ERK2 in cellular pro-
liferation and transformation also yielded conflicting conclusions
(Bourcier et al., 2006; Lefloch et al., 2008; Shin et al., 2010; Van-
taggiato et al., 2006; Voisin et al., 2010).
In this study, we used a combination of genetic approaches to
rigorously address the functions of ERK1 and ERK2 isoforms in
mouse embryonic development. We generated embryos car-
rying different combinations of Erk1 and Erk2 alleles and estab-
lished that the extent of embryonic and placental development
is dependent on the global ERK1/2 activity. Importantly, we
showed that transgenic overexpression of ERK1 rescues the
placental and embryonic phenotypes of ERK2-deficient mice
and the proliferation defects of ERK1/2-deficient mouse fibro-
blasts. Mice expressing exclusively ERK1 are viable, fertile,
and morphologically normal. Our results provide compelling
evidence for a functionally redundant role of ERK1 and ERK2
MAP kinases during development.RESULTS AND DISCUSSION
Disruption of Erk2 in the Whole Embryo Leads to Severe
Developmental Defects
The early lethality of ERK2-deficient embryos, consequent to a
cell-autonomous defect in trophoblast development (Saba-El-
Leil et al., 2003), precludes analysis of ERK2 functions in devel-
opment. To circumvent this problem, we generated a conditionalell Reports 12, 913–921, August 11, 2015 ª2015 The Authors 913
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allele of Erk2 and confirmed that the floxed (flox) and Cre-
excised deletion (D) alleles behave like wild-type and null alleles,
respectively (Figure S1). To investigate the impact of Erk2 defi-
ciency on the embryo per se, we crossed Erk2flox/flox mice with
Sox2:Cre transgenic mice (Hayashi et al., 2002) to inactivate
Erk2 exclusively in the epiblast and bypass extra-embryonic de-
fects. No viable Erk2D/D embryo was detected at E18.5 (0 of 41),
but some embryos survived up to E16.5 (Table S1). However,
these embryos exhibited major craniofacial abnormalities,
including a lack of mandible and tongue, shortened maxilla,
and cardiovascular malformations such as ventricular septal de-
fects and persistent truncus arteriosus (Figures 1A–1C). These
phenotypes are indicative of impaired neural crest development,
as previously reported (Newbern et al., 2008). In addition,
Erk2D/D embryos were smaller and, most notably, had short fore-
limbs and lacked hindlimbs (Figures 1A and 1B). Complete
excision of the Erk2 gene was confirmed on E10.5 embryos (Fig-
ure 1D). As previously observed by us and others, loss of Erk2
alleles does not result in compensatory expression of ERK1 pro-
tein. Interestingly, the anatomical location of these morpholog-
ical defects was closely related to areas displaying strong
ERK1/2 activity during development: frontonasal process, fore-
brain, pharyngeal arches, limb buds, and tailbud (Figure 1E; Cor-
son et al., 2003). As expected, ERK2-deficient embryos showed
a marked decrease of ERK1/2 activity at these sites.
Development of the Embryo and Placenta Is Dependent
on Total ERK1/2 Activity
We then investigated the effect of ERK1/2 gene dosage on em-
bryonic development by comparing the phenotypes of E14.5
placentas and embryos bearing different combinations of Erk1
and Erk2 alleles. We could establish a close correlation between
the total ERK1/2 activity in the placenta and its development
(Figures 2A–2D). Loss of a single Erk2 allele significantly
decreased the placental weight (Figure 2B) and surface area of
the labyrinth (Figures 2A and 2C). Additional disruption of Erk1
alleles exacerbated these effects. ERK2 was estimated to
contribute to 75%–80% of the global ERK1/2 activity in the
placenta (Figures 2D, S2B, and S2C). Close examination of the
placental architecture revealed no obvious differences among
different genotypes other than the reduced size and surface
area of the labyrinth layer, which forms a critical interface be-
tween maternal and fetal circulation, facilitating nutrient ex-
change and thereby impacting directly on embryonic growth
(Figure S2A). Many mouse mutants with a placental phenotype
are characterized by structural defects in the formation of the
labyrinth layer, resulting in reduced exchange of nutrients andFigure 1. Targeted Disruption of Erk2 in the Epiblast Leads to Severe
Erk2D/+;Sox2:Cre male mice were crossed with female Erk2flox/flox mice.
(A) Phenotypic appearance of embryos at E16.5. Erk2D/D embryos exhibit a sma
hindlimbs (indicated by arrows). The scale bar represents 3 mm.
(B) Alizarin red/Alcian blue staining of E16.5 embryos. The scale bar represents 3
(C) H&E staining of cross-sections of E16.5 hearts showing ventricular septal defec
left atrium; lv, left ventricle; pa, pulmonary artery; ra, right atrium; rv, right ventric
(D) Immunoblot analysis of ERK1/2 expression and activity in extracts from E10.
(E) Whole-mount immunohistochemistry analysis of phosphorylated ERK1/2 in E
pharyngeal arches (pa), forebrain (fb), liver primordia (l), and limb buds (lb). Cont
Cfetal growth restriction. These include ERK1/2 (Hatano et al.,
2003; this study) and their upstream kinase MEK1 (Giroux
et al., 1999). Notably, embryos with the same Erk1/2 alleles but
developing from placentas carrying different allelic combination
have distinct weights (Figures S2D–S2L), emphasizing the
importance of the role of placental ERK1/2 activity in controlling
embryonic growth.
The extent of embryonic development was also related to total
ERK1/2 activity. Embryos with two Erk2 alleles were similar in
size and weight irrespective of ERK1 activity (Figures 2E–2G).
Embryos with one Erk2 allele were morphologically normal, but
their weight decreased proportional to the number of Erk1
alleles. Specifically, we noted a progressive delay in the emer-
gence of digits during limb development with the gradual reduc-
tion in ERK1/2 activity (Figures 2E and 2G). Animals with a single
allele of Erk2 (Erk1/;Erk2D/+) were born but die within the first
hours of life. Finally, embryos with one Erk1 allele (Erk1+/;
Erk2D/D) were very small and their development stopped prema-
turely at E10.5 (Figure S2M). These results reveal a tight relation-
ship between ERK1/2 protein dosage and developmental
outcome, suggesting that ERK1 and ERK2 act redundantly dur-
ing embryonic development.
Transgenic Expression of ERK1Rescues Embryonic and
Placental Defects Associated with the Loss of ERK2
To further address this question, we next asked whether ERK1
could substitute for ERK2 inmouse development. We first gener-
ated knockin mouse models in which the mouse Erk1 or Erk2 (as
control) cDNA sequence was inserted into exon 1 of the Erk2
gene. However, both Erk1 and Erk2 knockin alleles were ex-
pressed at much lower levels than endogenous Erk2, precluding
the use of these mutant mice for quantitative phenotypic ana-
lyses. As an alternative strategy, we generated a transgenic
mouse that ubiquitously expresses ERK1 from the chicken
beta-actin promoter (Figure S3A). This ubiquitous promoter di-
rects constitutive transgene expression during all developmental
stages, from unfertilized eggs onward, and in adult tissues
(Okabe et al., 1997). We showed that TgERK1 mRNA (Fig-
ure S3B) and protein (Figure S3C) were expressed at all develop-
mental stages examined, from E10.5 to E18.5. Expression of
TgERK1 did not affect the expression level of ERK2 isoform.
TgErk1 mice were crossed to Erk2D/+ heterozygous mice, and
the F1 Erk2D/+;TgErk1 progeny was intercrossed to generate
Erk2D/D;TgErk1 mice. At E14.5, whereas Erk2D/D embryos were
never found in litters, Erk2D/D;TgErk1 embryos were recovered
in Mendelian proportions (Table S2). Erk2D/D;TgErk1 embryos
were morphologically indistinguishable from Erk2+/+ embryosMorphological Defects
ller size, shortened maxilla, lack of mandible, short forelimbs, and absence of
mm.
ts (vsd) and persistent truncus arteriosus (pta) in Erk2D/D embryos. ao, aorta; la,
le.
5 embryos.
10.5 embryos. Strong ERK1/2 activity localizes to frontonasal process (fnp),
, control without primary antibody. The scale bar represents 300 mm.
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Figure 2. The Extent of Placental and Embryonic Development Is Dependent on Global ERK1/2 Activity
Two types of crosses were performed to obtain placentas and embryos of the desired genotypes. Erk2D/+;Sox2:Cremales were crossed with Erk2flox/flox females,
and Erk1+/;Erk2D/+;Sox2:Cre males were crossed with Erk1/;Erk2flox/flox female mice.
(legend continued on next page)
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throughout embryonic development, from E10.5 to birth (Fig-
ure 3A), and had comparable weight (Figure 3B). Craniofacial
and limb defects resulting from absence of ERK2 were
completely rescued, as well as cardiac malformations (Fig-
ure S3D). TgErk1 restored the decrease in placental weight
observed upon the loss of one Erk2 allele (Figure 3C). Notably,
the architecture and weight of Erk2D/D;TgErk1 placentas were
identical to that of Erk2+/+ placentas (Figures 3C and 3D). We
confirmed by quantitative immunoblotting that ectopic expres-
sion of TgERK1 restores normal global ERK1/2 activity in
Erk2D/D;TgErk1 embryos and placentas (Figures 3E and 3F).
Importantly, the spatial pattern of ERK signaling in intact Erk2D/D
TgERK1-expressing embryos was similar to that of phenotypi-
cally normal embryos expressing one or two alleles of Erk2 (Fig-
ures S3E and 1E).
Mice Overexpressing Exclusively ERK1 Isoform Are
Viable, Morphologically Normal, and Fertile
Adult Erk2D/D;TgErk1 animals were also found in Mendelian pro-
portions (Table S2) and appeared morphologically normal (Fig-
ure 4A). Whereas Erk2D/+ mice are significantly smaller than
wild-type mice, Erk2D/D;TgErk1 mice had a normal weight (Fig-
ure 4B). Macroscopic examination of organs from Erk2D/D;
TgErk1 animals at 8 weeks did not reveal any abnormality (Fig-
ure S3F). Detailed histological analyses further confirmed the
normal architecture of tissues (Figure S3G). No difference could
be observed in the localization and extent of phospho-ERK1/2
activity in tissues from Erk2+/+ and Erk2D/D;TgErk1 animals (Fig-
ure 4C). TgERK1 expression was detected in all tissues exam-
ined (Figure S3H). It is noteworthy that the ERK1 transgene
was expressed at high levels in several tissues, such as muscle,
pancreas, heart, kidney, or stomach, but that the global ERK1/2
activity was comparable between Erk2+/+ and Erk2D/D;TgErk1
tissues (Figure S3H). This indicates that the steady-state activa-
tion of ERK1/2 is very robust against perturbations of ERK pro-
tein levels, confirming previous findings obtained in cultured
cell lines (Fritsche-Guenther et al., 2011). Whereas multiple
post-translational mechanisms may contribute to the observed
robustness, analysis of in vitro cellular models suggests that
negative feedback to RAF plays amajor role in conferring robust-
ness to long-term ERK1/2 signaling (Fritsche-Guenther et al.,
2011). Our results demonstrate the robustness of ERK1/2
signaling at the organismal level.
Erk2D/D;TgErk1 animals exhibited no overt phenotype after
12 months. We also tested whether these mice are fertile. Inter-
crossed Erk2D/D;TgErk1 animals were able to reproduce and
gave rise to normal progeny (Figures 4D and 4E). Finally, we in-(A) Placental sections of E14.5 embryosweremade at the chorioallantoic region an
bar represents 1 mm.
(B and C) The weight (B) of E14.5 placentas and the surface of sectioned labyrin
(D) Immunoblot analysis of ERK1/2 in extracts from E14.5 placentas. A represe
individual placentas.
(E) Phenotypic appearance of embryos of the indicated genotypes. Bottom pane
(F) Weight of E14.5 embryos.
(G) Immunoblot analysis of ERK1/2 in extracts from E10.5 embryos. A representa
Erk1 and Erk2 genes are represented by green and red circles, respectively. W
**p < 0.01; ***p < 0.001.
Ctercrossed Erk1+/;Erk2D/D;TgErk1 mice and generated viable
and morphologically normal Erk1/;Erk2D/D;TgErk1 adult ani-
mals, thus demonstrating that TgERK1 is able to compensate
for both endogenous ERK1 and ERK2 proteins (Table S3). Alto-
gether, our results demonstrate that overexpression of ERK1 can
compensate for the absence of ERK2 in Erk2/ mice.
We also analyzed the ability of TgERK1 to rescue the prolifer-
ative defects of ERK1/2 mutant mouse embryonic fibroblasts
(MEFs) in vitro (Voisin et al., 2010). Erk2D/D;TgErk1MEFs prolifer-
ated at similar rate than wild-type MEFs, whereas Erk2D/D
MEFs showed slower proliferation as previously documented
(Figure S4A). Importantly, expression of TgERK1 completely
rescued the proliferation arrest and senescence induction
observed in ERK1/2 double-knockout MEFs (Voisin et al.,
2010). TgERK1 was activated with similar kinetics as endoge-
nous ERK1 and ERK2, and its expression fully restored the
normal phosphorylation of a panel of ERK1/2 substrates (Fig-
ure S4B). These included Fra-1, which has been described as
an ERK2-specific target (Shin et al., 2010). Similarly, expression
of TgERK1 conferred normal transcriptional regulation of ERK1/2
target genes upon EGF stimulation (Figure S4C).
The question of ERK1 and ERK2 functional redundancy has
been a subject of intense research and controversy in the signal
transduction field. Several studies have argued for specific
roles of ERK1 and ERK2 MAP kinases based on the genetic
inactivation of one of the two isoforms by homologous recombi-
nation or RNAi in cultured cells andmice (Bost et al., 2005; Bour-
cier et al., 2006; Fre´min et al., 2007; Guihard et al., 2010; Radtke
et al., 2013; Satoh et al., 2007; Shin et al., 2010; Vantaggiato
et al., 2006). However, these studies did not take into account
the global ERK1/2 activity in the analysis of the phenotypes re-
sulting from Erk1 or Erk2 inactivation. This aspect is crucial as
ERK1 and ERK2 are differently expressed in many cell lines
and tissues, and ERK2 is the predominantly expressed isoform
in most mouse tissues (Figure S3H). Our study now provides
compelling genetic evidence for a functionally redundant role
of ERK1 and ERK2 MAP kinases. By highlighting the close rela-
tionship between the extent of embryonic development and the
global level of ERK1/2 activity, we propose that a threshold of
ERK1/2 activity determines normal developmental progression
(Figure 4F). The two redundant isoforms of ERK1/2 provide a
pool of kinases available for activation, and different thresholds
of activity are required for executing different developmental de-
cisions in specific tissues. Because ERK2 is the predominantly
expressed kinase in the mouse, loss of ERK2 results in a larger
spectrum of phenotypes that can be rescued simply by
increasing ERK1 expression as demonstrated here. However,d stainedwith H&E to visualize the labyrinth architecture (dotted line). The scale
th (C) were measured.
ntative blot is shown. Quantification of ERK activity was performed on three
ls, detail of developing toes.
tive blot is shown. Quantification was performed on three individual embryos.
ild-type and null alleles are symbolized by filled and empty circles. *p < 0.05;
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Figure 3. Transgenic Expression of ERK1 Rescues the Developmental Defects of ERK2-Deficient Embryos
Erk2D/+ mice were crossed with Erk2D/+;TgErk1 mice.
(A) Phenotypic appearance of embryos from E10.5 to E16.5 and newborn mice.
(B) Weight of E14.5 embryos.
(C) Weight of E14.5 placentas.
(D) H&E staining of sagittal sections from E14.5 placentas. The scale bar represents 1 mm.
(E and F) Immunoblot analysis of ERK1/2 in extracts from E14.5 placentas (E) and E10.5 embryos (F). Quantification of ERK1/2 activity and expression was
performed on three individual samples and is reported as mean ± SEM. The value of wild-type mice was set at 100%. **p < 0.01; ***p < 0.001.
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Figure 4. Characterization of Erk2D/D;TgErk1 Mice
Erk2D/+ mice were crossed with Erk2D/+;TgErk1 mice.
(A) Phenotypic appearance of Erk2D/D;TgErk1 mice at 8 weeks.
(B) Weight of 8-week-old female and male mice. *p < 0.05; **p < 0.01.
(C) Immunohistochemical staining for phospho-ERK1/2 in muscle, liver, intestine, and kidney. The scale bar represents 50 mm.
(D and E) Erk2D/D;TgErk1 mice were intercrossed and gave birth to normal progeny. Phenotypic appearance of newborn (D) and 8-week-old adult (E) mice.
(F) Schematic diagram of the extent of mouse embryonic development as a function of ERK1/2 gene dosage. Blue circle represents TgErk1 transgene. *These
embryonic phenotypes are only observed upon epiblast-specific inactivation of Erk2 to bypass extra-embryonic defects. Normal embryonic development
requires a minimal threshold of ERK1/2 activity that we estimate to be the sum of one allele of Erk1 and Erk2.
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we cannot definitely exclude that ERK1 and ERK2 exert non-
redundant functions in adult animals, in a normal or pathological
context.
The implications of our findings are important and wide
ranging. The ERK1/2 MAP kinase pathway is a key regulator of
several cellular responses, but a comprehensive picture of its
physiological functions has been hampered in many studies by
a lack of understanding of the individual roles of the two ERK iso-
forms. Most importantly, deregulation of the ERK1/2 pathway is
causally linked to a group of human congenital disorders known
as RASopathies and to cancer. Small-molecule inhibitors of
BRAF andMEK1/2 have been approved for the treatment of met-
astatic melanoma, and the first inhibitor of ERK1/2 has just
entered into clinical evaluation. Because all these compounds
are assumed to exert their clinical activity mainly through inhibi-
tion of their downstream effectors ERK1 and ERK2, it is crucial to
understandwhether the two isoforms exert specific or redundant
functions.
EXPERIMENTAL PROCEDURES
Manipulation of Mice
All mice were bred under standard conditions at the Institute for Research in
Immunology and Cancer. Mice were housed under specific pathogen-free
conditions in filter-topped isolator cages under a 12/12 hr light/dark cycle
with access to food and water ad libitum. Animals were handled in strict accor-
dance with good animal practice as defined by the relevant local animal wel-
fare bodies, and all experiments were approved by the Canadian Council on
Animal Care (CCAC).
Gene Targeting and Generation of Transgenic Strains
We generated a conditional Erk2 allele by flanking exon 3 of the Erk2 gene with
loxP sites (Figure S1). The targeting vector was linearized and electroporated
into G4 ESCs. Recombinant clones were selected with G418 and screened by
Southern blot analysis for homologous recombination. Correctly targeted ESC
clones were injected into C57BL/6 blastocyst-stage embryos to produce
chimeric mice, and germline transmission was obtained from two independent
clones. For the conditional Erk2 allele, the floxed neomycin resistance cassette
was removed by mating Erk2floxneo/+ male with Zp3:Cre female mice that ex-
press Cre recombinase in growing oocytes.
The TgErk1 construct was obtained by cloning the full-length mouse ERK1
cDNA into the EcoRI site of pCAGGS vector containing the cytomegalovirus
enhancer, chicken beta-actin promoter, beta-actin intron, and a rabbit
b-globin polyadenylation signal (Okabe et al., 1997). pCAGGS was kindly
provided by F. Charron (Universite´ de Montre´al). The SalI-PsiI linearized trans-
genic construct (3.7 kb) was microinjected into the pronucleus of FVB/N fertil-
ized oocytes, and the resulting embryos were implanted into pseudopregnant
mice. Mice expressing the TgErk1 transgene were identified by PCR analysis.
Two independent founder lines were selected and bred with CD1 mice.
All the strains weremaintained in amixed CD1 genetic background. For gen-
otyping analysis, genomic DNA from embryos or tails was isolated by protein-
ase K treatment in SDS buffer.
Histological and Immunohistochemistry Methods
For staining with H&E, embryos, placentas, and tissues were fixed in formalin
for at least 48 hr, embedded in paraffin, sectioned, and stained according to
standard procedures. To calculate the labyrinth surface area, placentas
were sectioned longitudinally at the chorioallantoic region, scanned, and
analyzed using The Nanozoomer Digital Pathology (NDP) system (Hama-
matsu). For staining of bone and cartilage, embryos were fixed in ice-cold
95% ethanol overnight and then stained with 0.02% Alcian Blue and 0.005%
Alizarin Red in 5% acetic acid and 70% ethanol for 24 hr. Soft tissues were
cleared in 1% KOH for 24 hr, and the samples were incubated in solutions
of increasing concentration of glycerol according to standard protocols.920 Cell Reports 12, 913–921, August 11, 2015 ª2015 The AuthorsWhole-mount immunohistochemistry analysis of phospho-ERK1/2 was per-
formed as described previously (Corson et al., 2003). Briefly, E10.5 embryos
were rapidly dissected in ice-cold PBS and transferred immediately to cold
8% paraformaldehyde overnight to preserve endogenous ERK1/2 signaling.
Embryos were dehydrated in methanol, bleached with 5% H2O2, rehydrated,
blocked with BSA-TBST (5% BSA in TBS [10 mM Tris-HCl (pH 7.5), 150 mM
NaCl] and 0.1% Triton X-100), and incubated with primary anti-phospho-
ERK1/2 antibody (1:250) overnight. The embryos were washed six times, incu-
bated with biotinylated secondary antibody overnight, washed again six times,
and incubated with Vectastain ABC peroxidase kit (Vector Laboratories). For
standard immunohistochemistry, tissue sections were washed three times in
TBS, quenched for 5 min in 10% methanol, 1% H2O2 in TBS, and permeabi-
lized for 15 min in 0.2% Triton X-100/TBS. The sections were incubated with
anti-phospho-ERK1/2 antibody (1:100) for 2 hr at 37C. Tissue sections
were then washed three times in TBS, incubated with biotinylated anti-IgG
secondary antibody (1:250) for 2 hr at room temperature, washed three times,
incubated with avidin-biotin complex (1:500; Vector Laboratories) for 1 hr,
washed three times, and finally revealed in diaminobenzidine substrate solu-
tion for 30 min.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.07.011.
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